22-May-2026
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Globe Newswire (Wed, 20-May 9:00 AM ET)
Codexis Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:05 PM ET)
Codexis to share RNA manufacturing advances at TIDES USA
Globe Newswire (Wed, 29-Apr 9:00 AM ET)
Codexis to Report First Quarter 2026 Financial Results on May 7
Globe Newswire (Thu, 23-Apr 9:00 AM ET)
Market Chameleon (Thu, 12-Mar 5:52 AM ET)
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Globe Newswire (Wed, 11-Mar 4:05 PM ET)
Market Chameleon (Thu, 5-Mar 6:08 AM ET)
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform
PRNewswire (Wed, 4-Mar 10:06 AM ET)
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Globe Newswire (Wed, 25-Feb 9:00 AM ET)
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Codexis trades on the NASDAQ stock market under the symbol CDXS.
As of May 22, 2026, CDXS stock price declined to $2.49 with 838,009 million shares trading.
CDXS has a beta of 2.36, meaning it tends to be more sensitive to market movements. CDXS has a correlation of 0.13 to the broad based SPY ETF.
CDXS has a market cap of $226.26 million. This is considered a Small Cap stock.
Last quarter Codexis reported $15 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $631,544 and exceeded earnings estimates by $.01.
In the last 3 years, CDXS traded as high as $6.08 and as low as $.96.
The top ETF exchange traded funds that CDXS belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.
CDXS has underperformed the market in the last year with a price return of +1.2% while the SPY ETF gained +29.1%. However, in the short term, CDXS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +112.8% vs +8.4% return in SPY. But in the last 2 weeks, CDXS shares have been beat by the market, returning -12.6% compared to an SPY return of +1.1%.
CDXS support price is $2.39 and resistance is $2.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDXS shares will trade within this expected range on the day.